Thus, our results extend the potential use of Fas-ASO treatment to fatty liver disease, i.e., to improve obesity-associated mitochondrial dysfunction, NAFLD, and insulin resistance. Here, FAS is linked to obesity due to melanocortin 4 receptor deficiency.